Biogen Inc. $BIIB Position Increased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. raised its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 175.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,094 shares of the biotechnology company’s stock after buying an additional 6,436 shares during the period. Crossmark Global Holdings Inc.’s holdings in Biogen were worth $1,776,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. WPG Advisers LLC grew its holdings in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the last quarter. First Horizon Corp acquired a new position in shares of Biogen in the 4th quarter worth $30,000. GoalVest Advisory LLC acquired a new position in shares of Biogen in the 4th quarter worth $35,000. Accredited Wealth Management LLC grew its holdings in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares during the last quarter. Finally, Elevation Wealth Partners LLC grew its holdings in shares of Biogen by 412.8% in the 4th quarter. Elevation Wealth Partners LLC now owns 200 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 161 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Guggenheim boosted their price target on shares of Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Freedom Capital upgraded Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Wall Street Zen upgraded shares of Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. TD Cowen boosted their target price on Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Finally, HSBC lifted their target price on shares of Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $214.23.

Biogen Price Performance

Shares of Biogen stock opened at $199.36 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. Biogen Inc. has a fifty-two week low of $119.18 and a fifty-two week high of $202.41. The firm has a fifty day moving average price of $184.68 and a two-hundred day moving average price of $178.56. The company has a market cap of $29.43 billion, a PE ratio of 21.39, a price-to-earnings-growth ratio of 1.73 and a beta of 0.19.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts expect that Biogen Inc. will post 14.31 EPS for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.